Riluzole is a neuroprotective drug that activates TREK/TRAAK channels and is licensed for the treatment of amyotrophic lateral sclerosis and in clinical trial for spinal cord injuries [7, 8, 15]. This evidence concerns the gene KCNK2 and spinal cord injury.